Enlivex Therapeutics Soars 14.61% on Clinical Trial Data

Enlivex Therapeutics' stock surged 14.61% in pre-market trading on August 15, 2025, driven by significant developments in its clinical trials and upcoming data presentations.

The company is set to present 3-month topline data from its Phase IIa trial of ENX-CL-05-001, a multi-center, two-stage Phase I/II trial. This presentation is scheduled for August 18, 2025, and will provide a detailed analysis of the trial's progress and results, which is expected to influence investor sentiment and stock performance.

Enlivex Therapeutics has also announced a webinar to share the 3-month topline results from its Phase IIa trial for knee osteoarthritis. This event is scheduled for August 18, 2025, at 8:00 AM ET, and is anticipated to attract significant attention from investors and analysts.